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PRELIMINARY AND SHORT REPORT
THE TREATMENT OF LUPUS ERYTHEMATOSUS WITH CHLOROQUINE
SULPHATE*
GEORGB HARVEY, M.B., CH.B. AND THOMAS COCHEANE, B.Sc., M.D., F.R.F.P.S.
In a recent article (1) we described our results of the treatment of lupus erythematosus
with mepacrine hydrochloride (Atabrine). We were unable to determine the mode of action
of mepacrine but to eliminate the possibility that the drug acted by its antimalarial prop-
erties, two other substances used in the treatment of malaria namely chioroquine sulphate
and proquanil hydrochloride were given each to 10 cases of lupus erythematosus. No re-
sponse was obtained with the latter compound but 2 cases treated with chioroquine sulphate
cleared completely. We decided that these cases were possible examples of spontaneous re-
mission of the disease. One of these 2 cases relapsed after treatment was stopped but on
further treatment with chioroquine sulphate the disease again cleared. It was decided there-
fore to try this drug in a series of cases using larger doses.
RESULTS OF TREATMENT
Thirty cases of lupus erythematosus have been treated with chioroquine sulphate and
the results are given in Table I. All cases were of the chronic discoid type and 9 cases had
received no previous treatment.
Nivaquine (May and Baker) tablets each of 200 mg. and containing 150 mg. of chioro-
quine base were used throughout. The dosage of nivaquine used varied only slightly from
case to case. For the first two weeks 150 mg. chioroquine base was given daily. The dosage
was then increased to 300 mg. daily for four weeks and subsequently reduced to 150 mg.
daily for the next four weeks. Occasionally the patient was maintained on the higher dose
for five or six weeks.
Nine cases responded excellently to treatment and cleared or healed completely while
another 9 cases showed a satisfactory improvement. Of these 9 cases several were of long
duration and now show sound scar tissue in the centers of lesions which are much less active.
In Table II a comparison is made with the results from the series of lupus erythematosus
treated with mepacrine. A sufficient period has not yet elapsed to allow a definite follow
up study of the present chloroquine treated series.
COMPLIcATIONS
Only one major complication appeared to develop from chloroquine sulphate. A female
patient, forty-two years of age, had a hematemesis ten days after starting treatment.
Roentgenological examination of the gastro-intestinal tract revealed a spastic duodenal
cap but no evidence of ulceration.
Two other cases had difficulty in focusing their near vision. In one patient the drug was
stopped for forty eight hours and then resumed at a reduced level with no further upset.
In the other patient treatment was withdrawn and vision soon returned to normal.
COMMENT
A comparison of our results obtained with mepacrine hydrochloride and chloroquine
sulphate shows that the latter compound is as good as the former and it is less toxic. No
dermal complications have appeared and there is no discoloration of the skin. In the treat-
ment of lupus erythematosus in women this advantage is important.
* From the Department of Dermatology, Royal Infirmary, Glasgow.
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TABLE I
TYPE OF CASE NUMBER
RESULTS OF TREATMENT
ceiit Good Slight chaned
REACTIONS
Fresh
Old
9
21
4
5
2
7
2
2
1
7
1 Severe
2Mild
Total 30 9 9 4 8 3
TABLE II
METHOD OF TREATMENT NUMBER
RESULTS OF TREATMENT
REACTIONS
Excellent Good
Chioroquine Sulphate
Mepacrine Hydrochloride
30
62
9
20
9 18
17 37
3
8
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It would seem that our two previous successful cases were perhaps not due to spontaneous
cure but could be attributed to chioroquine sulphate. Our greater number of successes in
this series may be due to the increased dosage and we think that even better results might
be obtained if a large loading dose was given during the first two weeks and then gradually
reduced. Although chloroquine sulphate still gives apparently inferior results to bismuth
we are of the opinion that it is the drug of choice in early cases of lupus erythematosus be-
cause of its efficacy, its low toxicity and ease of administration. The drug also appears to
give a satisfactory response in some cases which are resistant to mepacrine.
The mode of action of chloroquine sulphate remains unknown. From the structural
formulae given in Fig. 1 it is seen that chloroquine sulphate and mepacrine hydrochloride
are chemically related. The two compounds have the same diethylamino-1-methylbutyl-
amino side chain. We are hoping in the future to have prepared and, if found suitable, use
other compounds with this side chain.
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Thirty cases of lupus erythematosus were treated with chloroquine sulphate (nivaquine).
The results obtained are as good as those from mepacrine hydrochloride (atabrine).
The drug is much less toxic and so far has caused no dermal complications. The mode of
action of chioroquine sulphate is unknown but future lines of investigation are suggested.
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